Standard Operating Procedure: Safe Administration of Chemotherapy

This Standard Operating Procedure (SOP) outlines the mandatory clinical requirements, safety protocols, and administrative workflows for the preparation and administration of chemotherapy agents. Given the high-alert nature of these medications, this document prioritizes patient safety, caregiver protection, and the prevention of medication errors through a rigorous "double-check" verification system. Strict adherence to these steps is required to maintain compliance with oncology nursing standards and hazardous drug handling regulations (USP <800>).

1. Pre-Administration Preparation and Verification

• Verification of Orders: Ensure the oncology provider has signed the chemotherapy order. Confirm that the dosage is calculated based on current height, weight, and Body Surface Area (BSA).
• Lab Review: Review the patient’s most recent Complete Blood Count (CBC) and Comprehensive Metabolic Panel (CMP). Ensure ANC (Absolute Neutrophil Count), platelets, and organ function (liver/renal) are within acceptable ranges per protocol.
• Informed Consent: Confirm that the patient has a signed, valid informed consent form on file for the specific treatment regimen.
• Patient Identification: Use two patient identifiers (Full Name and Date of Birth) to confirm identity against the Electronic Health Record (EHR).
• PPE Procurement: Don appropriate Personal Protective Equipment (PPE) for handling hazardous drugs, including chemotherapy-rated gloves (double-gloving), non-permeable gowns, and eye protection as necessary.

2. Drug Handling and Verification

• Independent Double-Check: A second oncology-certified nurse or pharmacist must verify the drug, dose, route, and expiration date against the patient's chart. Both staff members must sign off on the administration record.
• Label Integrity: Inspect each medication bag for leaks, precipitates, or discoloration. Ensure labels clearly state the drug name, concentration, and patient name.
• Spill Kit Readiness: Verify that a chemotherapy spill kit is immediately accessible in the treatment area before any drugs are removed from the transport container.

3. Patient Assessment and IV Access

• IV Site Patency: Inspect the venous access device (VAD). For peripheral lines, verify clear blood return. For central lines (PICC/Port), confirm placement and flushing protocols are met.
• Extravasation Risk Assessment: Assess the integrity of the vessel to be used. If any signs of infiltration (swelling, pain, erythema) are present, do not initiate infusion.
• Pre-Medication Administration: Administer prescribed antiemetics, corticosteroids, or antihistamines at the specified time intervals prior to starting the chemotherapy agent.

4. Infusion and Monitoring

• Initiation: Use closed-system transfer devices (CSTD) if available. Infuse the drug via a dedicated primary line or a piggyback configuration, following facility policies regarding "line flushing" and compatibility.
• Continuous Surveillance: Monitor the patient for immediate hypersensitivity reactions (chills, dyspnea, hypotension, urticaria). Stay with the patient during the initial 15 minutes of the infusion.
• Documentation: Record the start time, rate of infusion, and nurse signatures in the medication administration record (MAR).

5. Post-Administration and Waste Management

• Line Flushing: Flush the IV line with the recommended volume of compatible IV fluid to ensure the full dose has been delivered.
• Hazardous Waste Disposal: Place all used syringes, IV bags, and tubing into designated "Chemotherapy Waste" (yellow or black) containers.
• Final Assessment: Re-assess the patient for any delayed side effects before discharge. Provide clear instructions on symptoms that require immediate emergency intervention.

Pro Tips & Pitfalls

• Pro Tip: Always calculate the dose yourself before checking it against the pharmacy's calculation. Never rely solely on the machine or another colleague’s math.
• Pro Tip: If a drug requires a vesicant, perform a "dry run" with a saline flush to ensure perfect venous access before connecting the chemo line.
• Pitfall: Do not rush the "Double-Check." Most errors occur during high-volume periods when nurses feel pressured to speed up the verification process.
• Pitfall: Never ignore a patient’s report of "burning" or "tingling" at the site. Stop the infusion immediately—do not flush—if extravasation is suspected.

Frequently Asked Questions (FAQ)

Q: What should I do if the drug bag appears cloudy? A: Do not administer the medication. Immediately return the bag to the pharmacy for inspection and documentation. The drug may have precipitated or undergone chemical degradation.

Q: Can I infuse chemotherapy and other non-chemo medications concurrently? A: Generally, no. Chemotherapy should be administered through a dedicated line to avoid drug-drug interactions and to ensure that in the event of an extravasation or reaction, you are not administering other agents simultaneously.

Q: How long must I keep the patient under observation after the infusion? A: Observation requirements vary by drug protocol. However, it is standard practice to monitor for at least 30 to 60 minutes post-infusion for delayed hypersensitivity, depending on the specific regimen and the patient’s history.